Martin Jädersten

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BLOOD. 2024;144(11):1221-1229
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Sirenko M; Bernard E; Creignou M; Domenico D; Farina A; Arango Ossa JE; Kosmider O; Hasserjian R; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Gurnari C; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Sander B; Orna E; Zoldan K; Eder LN; Sperr WR; Thalhammer R; Ganster C; Adès L; Tobiasson M; Palomo L; Della Porta MG; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Ogawa S; Fontenay M; Jansen JH; Cervera J; Ebert BL; Bejar R; Greenberg PL; Gattermann N; Malcovati L; Cazzola M; Beck DB; Hellström-Lindberg E; Papaemmanuil E
Article: JOURNAL OF INTERNAL MEDICINE. 2024;296(1):53-67
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes
Creignou M; Bernard E; Gasparini A; Tranberg A; Todisco G; Moura PL; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Lorenz F; Rasmussen B; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Elena C; Ferrari J; Galli A; Pozzi S; Malcovati L; Edgren G; Crowther MJ; Jaedersten M; Papaemmanuil E; Hellstroem-Lindberg E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(12):1378-1390
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Ejerblad E; Olesen G; Bjorklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Lundstrom LY; von Bahr L; Baltzer-Sollander K; Jadersten M; Kytola S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellstrom-Lindberg E
Article: BLOOD ADVANCES. 2024;8(2):343-352
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML
Jimenez-Chillon C; Othman J; Taussig D; Jimenez-Vicente C; Martinez-Roca A; Tiong IS; Jain M; Aries J; Cakmak S; Knapper S; Kristensen DT; Murthy V; Galani JZ; Kallmeyer C; Ngu L; Veale D; Bolam S; Orfali N; Parker A; Manson C; Parker J; Erblich T; Richardson D; Mokretar K; Potter N; Overgaard UM; Roug AS; Wei AH; Esteve J; Jadersten M; Russell N; Dillon R
Article: BLOOD. 2024;143(3):233-242
Malignancy-associated hemophagocytic lymphohistiocytosis in Sweden: incidence, clinical characteristics, and survival
Lofstedt A; Jadersten M; Meeths M; Henter J-I
Article: BLOOD. 2023;142(1):73-89
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
Dolinska M; Cai H; Mansson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-SF; Deneberg S; Soederlund S; Jaedersten M; Ungerstedt J; Tobiasson M; Ostman A; Mustjoki S; Stenke L; Le Blanc K; Hellstroem-Lindberg E; Lehmann S; Ekblom M; Olsson-Stroemberg U; Sigvarosson M; Qian H
Article: LEUKEMIA. 2023;37(5):1103-1112
Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective
Berggren DM; Garelius H; Hjelm PW; Nilsson L; Rasmussen B; Weibull CE; Lambe M; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Article: HAEMATOLOGICA. 2023;108(4):1015-1025
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
Nilsson C; Linde F; Hulegardh E; Garelius H; Lazarevic V; Antunovic P; Cammenga J; Deneberg S; Eriksson A; Jadersten M; Bjorkvall CK; Mollgard L; Wennstrom L; Olander E; Hoglund M; Juliusson G; Lehmann S
Article: SCIENCE IMMUNOLOGY. 2022;7(78):eadd3330
Notch-dependent cooperativity between myeloid lineages promotes Langerhans cell histiocytosis pathology
Kvedaraite E; Milne P; Khalilnezhad A; Chevrier M; Sethi R; Lee HK; Hagey DW; Greenwood TVB; Mouratidou N; Jadersten M; Lee NYS; Minnerup L; Tan Y; Dutertre C-A; Benac N; Hwang YY; Lum J; Loh AHP; Jansson J; Teng KWW; Khalilnezhad S; Xu W; Resteu A; Tey HL; Guan NL; Larbi A; Howland SW; Arnell H; Andaloussi SEL; Braier J; Rassidakis G; Galluzzo L; Dzionek A; Henter J-I; Chen J; Collin M; Ginhoux F
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(6):925-940
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial
Jadersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzen S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Ostling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Hoglund M; Henter J-I; Herold N
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;198(4):721-728
Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma
Sveijer M; Greenwood TVB; Jadersten M; Kvedaraite E; Zetterberg H; Blennow K; Lourda M; Gavhed D; Henter J-I
Article: HAEMATOLOGICA. 2022;107(7):1528-1537
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
Osterroos A; Maia T; Eriksson A; Jadersten M; Lazarevic V; Wennstrom L; Antunovic P; Cammenga J; Deneberg S; Lorenz F; Mollgard L; Uggla B; Olander E; Aguiar E; Trigo F; Hoglund M; Juliusson G; Lehmann S
Article: NEJM EVID. 2022;1(7):evidoa2200008
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Bernard E; Tuechler H; Greenberg PL; Hasserjian RP; Arango Ossa JE; Nannya Y; Devlin SM; Creignou M; Pinel P; Monnier L; Gundem G; Medina-Martinez JS; Domenico D; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Takaori-Kondo A; Ishikawa T; Chiba S; Kasahara S; Miyazaki Y; Viale A; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Ohyashiki K; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellström-Lindberg E; Papaemmanuil E
Article: BONE MARROW TRANSPLANTATION. 2022;57(2):191-197
Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial
Walladbegi J; Henriksson R; Tavelin B; Svanberg A; Larfors G; Jadersten M; Schjesvold F; Mahdi A; Garming Legert K; Peterson DE; Jontell M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(12):991.e1-991.e9
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population
Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jadersten M; Hellstrom-Lindberg E; Gronbaek K; Ljungman P; Friis LS
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;107(2):219-228
Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes
Larfors G; Moreno Berggren D; Garelius H; Jadersten M; Nilsson L; Rasmussen B; Ejerblad E
Article: LEUKEMIA & LYMPHOMA. 2021;62(8):1973-1981
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study
Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf A; Deneberg S; Jadersten M; Antunovic P; Cammenga J; Mollgard L; Wennstrom L; Olander E; Ehinger M; Fogelstrand L; Hoglund M; Lazarevic VL
Article: NATURE COMMUNICATIONS. 2021;12(1):2474
A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia
Docking TR; Parker JDK; Jadersten M; Duns G; Chang L; Jiang J; Pilsworth JA; Swanson LA; Chan SK; Chiu R; Nip KM; Mar S; Mo A; Wang X; Martinez-Hoyer S; Stubbins RJ; Mungall KL; Mungall AJ; Moore RA; Jones SJM; Birol I; Marra MA; Hogge D; Karsan A
Article: ACTA PAEDIATRICA. 2021;110(4):1315-1321
Patients with both Langerhans cell histiocytosis and Crohn's disease highlight a common role of interleukin-23
Kvedaraite E; Lourda M; Han H; Tesi B; Mitchell J; Idestrom M; Mouratidou N; Rassidakis G; Greenwood TVB; Cohen-Aubart F; Jadersten M; Akefeldt SO; Svensson M; Kannourakis G; Bryceson YT; Haroche J; Henter J-I
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483
Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study
Berggren DM; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ungerstedt J; Ejerblad E
Article: NATURE MEDICINE. 2020;26(10):1549-1556
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Article: NATURE CELL BIOLOGY. 2020;22(5):526-533
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome
Martinez-Hoyer S; Deng Y; Parker J; Jiang J; Mo A; Docking TR; Gharaee N; Li J; Umlandt P; Fuller M; Jadersten M; Kulasekararaj A; Malcovati L; List AF; Hellstrom-Lindberg E; Platzbecker U; Karsan A
Article: BLOOD ADVANCES. 2020;4(6):1094-1101
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting
Juliusson G; Jadersten M; Deneberg S; Lehmann S; Mollgard L; Wennstrom L; Antunovic P; Cammenga J; Lorenz F; Olander E; Lazarevic VL; Hoglund M
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2019;8:7
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016
Carlsten M; Jadersten M; Hellstrom A; Littmann K; Melen CM; Junlen HR; Sonnevi K; Ljungman P; Bjorkstrand B; Wahlin BE
Article: PLOS ONE. 2019;14(2):e0212812
PCR with electrospray ionization-mass spectrometry on bronchoalveolar lavage for detection of invasive mold infections in hematological patients
Krifors A; Ozenci V; Ullberg M; Ackefors M; Jadersten M; Stralin K; Blennow O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;181(5):614-627
Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register
Berggren DM; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Article: HAEMATOLOGICA. 2017;102(3):498-508
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Scharenberg C; Giai V; Pellagatti A; Saft L; Dimitriou M; Jansson M; Jadersten M; Grandien A; Douagi I; Neuberg DS; LeBlanc K; Boultwood J; Karimi M; Jacobsen SEW; Woll PS; Hellstrom-Lindberg E
Article: ONCOTARGET. 2016;7(16):22103-22115
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jadersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellstrom-Lindberg E
Article: BLOOD. 2015;126(2):233-241
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jadersten M; Jansson M; Elena C; Galli A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungstrom V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Lindberg EH
Article: NATURE COMMUNICATIONS. 2015;6:5901
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
Gerstung M; Pellagatti A; Malcovati L; Giagounidis A; Della Porta MG; Jaedersten M; Dolatshad H; Verma A; Cross NCP; Vyas P; Killick S; Hellstroem-Lindberg E; Cazzola M; Papaemmanuil E; Campbell PJ; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(28):3557-3564
Identification of Gene Expression-Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes
Pellagatti A; Benner A; Mills KI; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Verma A; McDonald E-J; Killick S; Hellstrom-Lindberg E; Bullinger L; Wainscoat JS; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(21):2662-2670
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
Article: HAEMATOLOGICA. 2011;96(7):963-971
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Mollgard L; Saft L; Treppendahl MB; Dybedal I; Norgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jadersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Gronbaek K; Lindberg EH
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):1971-1979
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jaedersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Goehring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellstrom-Lindberg E; Mufti GJ
Article: LEUKEMIA. 2010;24(9):1607-1616
Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34⁺ blasts in myelodysplastic syndrome
Carlsten M; Baumann BC; Simonsson M; Jadersten M; Forsblom A-M; Hammarstedt C; Bryceson YT; Ljunggren H-G; Hellstrom-Lindberg E; Malmberg K-J
Article: LEUKEMIA. 2010;24(4):756-764
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Verma A; Norbury CJ; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Article: HAEMATOLOGICA. 2009;94(12):1762-1766
Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
Jadersten M; Saft L; Pellagatti A; Goehring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellstrom-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;146(1):86-90
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes
Pellagatti A; Marafioti T; Paterson JC; Malcovati L; Della Porta MG; Jadersten M; Pushkaran B; George TI; Arber DA; Killick S; Giagounidis A; Hellstrom-Lindberg E; Cazzola M; Wainscoat JS; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(21):3607-3613
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
Jadersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellstrom-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;142(1):57-64
Haploinsufficiency of RPS14 in 5q-syndrome is associated with deregulation of ribosomal- and translation-related genes
Pellagatti A; Hellstrom-Lindberg E; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Fidler C; Cazzola M; Wainscoat JS; Boultwood J
Article: PLOS ONE. 2008;3(4):e1970
The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts
Boultwood J; Pellagatti A; Nikpour M; Pushkaran B; Fidler C; Cattan H; Littlewood TJ; Malcovati L; Della Porta MG; Jadersten M; Killick S; Giagounidis A; Bowen D; Hellstrom-Lindberg E; Cazzola M; Wainscoat JS
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2007;139(4):578-589
Gene expression profiling of CD34⁺ cells in patients with the 5q-syndrome
Boultwood J; Pellagatti A; Cattan H; Lawrie CH; Giagounidis A; Malcovati L; Della Porta MG; Jaedersten M; Killick S; Fidler C; Cazzola M; Hellstroem-Lindberg E; Wainscoat JS
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2007;104(27):11406-11411
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Pellagatti A; Jaedersten M; Forsblom A-M; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Helistroem-Lindberg E
Article: CANCER CONTROL. 2006;13 Suppl:17-25
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Goss TF; Szende A; Schaefer C; Totten PJ; Knight R; Jädersten M; Hellström-Lindberg E; List AF
Article: CLINICAL CANCER RESEARCH. 2005;11(17):6291-6299
Antiapoptotic role of growth factors in the Myelodysplastic syndromes:: Concordance between in vitro and in vivo observations
Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hollström-Lindberg E
Visa fler

Alla övriga publikationer

Editorial comment: HAEMATOLOGICA. 2023;108(7):1968-1971
Omalizumab alleviates pruritus in myeloproliferative neoplasms
Landtblom AR; Ungerstedt J; Hedlund A; Tobiasson M; Deneberg S; Jadersten M
Letter: BLOOD ADVANCES. 2022;6(16):4705-4709
The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS
Hofman IJF; Mortera-Blanco T; Moura PL; Vestlund J; Larsson SV; Elvarsdottir EM; Walldin G; Tobiasson M; Sander B; Dimitriou M; Jacobsen S-EW; Woll PS; Jadersten M; Hellstrom-Lindberg E
Letter: LEUKEMIA. 2022;36(5):1436-1439
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"
Rasmussen B; Gohring G; Bernard E; Nilsson L; Tobiasson M; Jadersten M; Garelius H; Dybedal I; Gronbaek K; Ejerblad E; Lorenz F; Flogegard M; Marcher CW; oster Fernstrom A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Norgaard JM; Saft L; Mollgard L; Hellstrom-Lindberg E
Letter: LEUKEMIA & LYMPHOMA. 2022;63(3):755-758
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation
Jadersten M; Boriskina K; Lindholm C; Westrom S; Cavelier L; Hellstrom-Lindberg E; Mielke S; Tobiasson M
Corrigendum: NATURE MEDICINE. 2021;27(5):927
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Corrigendum: NATURE MEDICINE. 2021;27(3):562
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Letter: BLOOD. 2019;134(18):1558-1561
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
Juliusson G; Hagberg O; Lazarevic VL; Olander E; Antunovic P; Cammenga J; Wennstrom L; Mollgard L; Brune M; Jadersten M; Deneberg S; Lehmann S; Derolf AR; Hoglund M
Meeting abstract: BLOOD. 2018;132:176
Resistance to Lenalidomide in Del(5q) MDS Is Mediated By Inhibition of Drug-Induced Megakaryocytic Differentiation
Martinez-Hoyer S; Mo A; Deng D; Jiang J; Docking R; Li J; Chan S; Umlandt P; Fuller M; Jadersten M; Hellstrom-Lindberg E; Platzbecker U; Parker J; Karsan A
Meeting abstract: LEUKEMIA RESEARCH. 2017;55:S138-S139
TARGETED SEQUENCING OF A COHORT OF 385 PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A MULTICENTER, POPULATION-BASED STUDY FROM SWEDEN
Creignou M; Ejerblad E; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Walldin G; Jansson M; Karimi M; Hellstrom-Lindberg E; Jadersten M
Meeting abstract: LEUKEMIA RESEARCH. 2017;55:S43-S44
RUNX1 LOSS OF FUNCTION DRIVES RESISTANCE TO LENALIDOMIDE IN DEL(5Q) MYELODYSPLASTIC SYNDROME PATIENTS
Martinez-Hoyer S; Mo A; Docking R; Li J; Chan S; Umlandt P; Fuller M; Jadersten M; Hellstrom-Lindberg E; Platzbecker U; Parker J; Karsan A
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S153
DEVELOPMENT AND IMPLEMENTATION OF A NEW BIOBANK SYSTEM
Jansson M; Walldin G; Ben Azenkoud A; Dimitriou M; Karimi M; Tobiasson M; Jadersten M; Tapia J; Lindberg EH
Meeting abstract: BLOOD. 2013;122(21):2779
Association Between Gene Expression Profiles and Commonly Mutated Genes In The Hematopoietic Stem Cells Of Patients With Myelodysplastic Syndromes
Pellagatti A; Gerstung M; Papaemmanuil E; Malcovati L; Giagounidis A; Della Porta MG; Jadersten M; Verma A; Vyas P; Killick S; Hellstrom-Lindberg E; Cazzola M; Campbell PJ; Boultwood J
Meeting abstract: BLOOD. 2011;118(21):56-57
A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS
Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jaedersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler CS
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2011;155(2):272-274
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Vyas P; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Editorial comment: HAEMATOLOGICA. 2011;96(2):177-180
Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
Jädersten M; Karsan A
Review: EXPERIMENTAL CELL RESEARCH. 2010;316(8):1390-1396
New clues to the molecular pathogenesis of myelodysplastic syndromes
Jadersten M; Helistrom-Lindberg E
Letter: LEUKEMIA. 2010;24(5):1062-1065
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia
Boultwood J; Perry J; Pellagatti A; Fernandez-Mercado M; Fernandez-Santamaria C; Calasanz MJ; Larrayoz MJ; Garcia-Delgado M; Giagounidis A; Malcovati L; Della Porta MG; Jadersten M; Killick S; Hellstrom-Lindberg E; Cazzola M; Wainscoat JS
Editorial comment: HAEMATOLOGICA. 2010;95(3):348-351
Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion
Jadersten M
Meeting abstract: BLOOD. 2009;114(22):306
Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Verma A; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S48
Lenalidomide abrogates the clonal advantage of del(5q) MDS stem cells via alteration of niche interactions
Scharenberg C; Jadersten M; Palmquist J; Forsblom L; Jansson M; Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S39
Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q)
Jadersten M; Saft L; Garelius H; Hast R; Nilsson L; Samuelsson J; Porwit A; Hellstrom-Lindberg E
Review: JOURNAL OF INTERNAL MEDICINE. 2009;265(3):307-328
Myelodysplastic syndromes: biology and treatment
Jadersten M; Hellstrom-Lindberg E
Thesis / dissertation: 2008
Studies of anemia in the myelodysplastic syndromes
Jädersten, Martin
Meeting abstract: LEUKEMIA RESEARCH. 2007;31:S35
Expression profiling of CD34+cells in patients with myelodysplastic syndromes:: differences between early and advanced cases and analysis of apoptosis-related genes
Pellagatti A; Cazzola M; Giagounidis A; Malcovati L; Della Porta MG; Jadersten M; Killick S; Fidler C; Cattan H; Bowen D; Aul C; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Meeting abstract: LEUKEMIA RESEARCH. 2007;31:S113-S114
Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need
Jadersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit-MacDonald A; Cazzola M; Hellstrom-Lindberg E
Meeting abstract: BLOOD. 2006;108(11):742A
Expression profiling of CD34+cells in patients with myelodysplastic syndromes:: Involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.
Pellagatti A; Cazzola M; Giagounidis A; Malcovati L; Della Porta MG; Jadersten M; Killick S; Fidler C; Oscier D; Bowen D; Aul C; Helistrom-Lindberg E; Wainscoat JS; Boultwood J
Published conference paper: BLOOD. 2005;106(3):803-811
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
Jädersten M; Montgomery SM; Dybedal I; Porwit-MacDonald A; Hellström-Lindberg E
Visa fler

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2008
Läkarexamen, Karolinska Institutet, 2000

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI